UK markets closed
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • FTSE 250

    20,338.96
    +93.53 (+0.46%)
     
  • AIM

    933.20
    +4.84 (+0.52%)
     
  • GBP/EUR

    1.1820
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • BTC-GBP

    20,366.32
    +511.53 (+2.58%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • DOW

    33,761.05
    +424.38 (+1.27%)
     
  • CRUDE OIL

    91.88
    -2.46 (-2.61%)
     
  • GOLD FUTURES

    1,818.90
    +11.70 (+0.65%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • HANG SENG

    20,175.62
    +93.19 (+0.46%)
     
  • DAX

    13,795.85
    +101.34 (+0.74%)
     
  • CAC 40

    6,553.86
    +9.19 (+0.14%)
     

Sartorius Stedim Biotech SA: Information on Document Availability

·2-min read

Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability

21-Jul-2022 / 08:21 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

 Aubagne, July 21, 2022

 

 

Information on Document Availability

The report on the first half 2022 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:

https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations

It contains the following information:

  • Business development for the period of January to June 2022 as well as the 2022 full year forecast for the Sartorius Stedim Biotech Group

  • Consolidated financial statements for the period ended June 30, 2022

 

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros.

 

Contact

Petra Müller     

Head of Investor Relations   

+49 (0)551.308.6035      

petra.mueller2@sartorius.com   

 

 

Regulatory filing PDF file

File: Sartorius Stedim Biotech - Rapport financier semestriel de janvier à juin 2022


Language:

English

Company:

Sartorius Stedim Biotech SA

Avenue de Jouques

13781 Aubagne

France

Phone:

+33 44 284 5600

E-mail:

info@sartorius-stedim.com

Internet:

www.sartorius-stedim.com

ISIN:

FR0013154002

Euronext Ticker:

DIM

AMF Category:

Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly financial report

EQS News ID:

1402595

 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting